Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 10 shares of common stock through a deferral plan.

Summary

• Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 10 shares of common stock on July 15, 2024.
• The shares were acquired at a price of $950.46 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Sulzberger's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it indicates director confidence, but it is not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

Director share acquisitions are a common occurrence and are often viewed as a sign of confidence in the company's prospects.

Comparison to Industry Standards

• Director share acquisitions are a standard practice across publicly traded companies.
• The use of deferral plans for director compensation is also a common practice.
• The specific details of the deferral plan and the timing of the share settlement are specific to Eli Lilly's compensation policies.

Stakeholder Impact

• The share acquisition by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, LLY, Gabrielle Sulzberger